The Board of Directors of Elekta AB (publ)(STO:EKTAB) has decided to utilize the
authorization received from the Annual General Meeting to repurchase shares in
Elekta`s new distribution policy is to distribute 30 percent or more of net
profit to shareholders in the form of dividends, share repurchases or comparable
Elekta`s Annual General Meeting on September 15, 2009 resolved to authorize the
Board to decide on the acquisition of a maximum of 10 percent of the total
number of shares in the company.
The Board has today decided to exercise the mandate by authorizing the executive
management to initiate, on appropriate occasion, the repurchase of shares in an
amount of MSEK 100 and not more than 650,000 shares, corresponding to 0.7
percent of the total number of outstanding shares in the company.
The purpose of the repurchase of own shares is firstly to align the Company`s
capital structure to the Company`s capital requirements and where appropriate to
be able to transfer shares in conjunction with the financing of company
acquisitions and other types of strategic investments and acquisitions. In
addition, the purpose is to facilitate hedging of costs and delivery in relation
to the Performance Share Program 2009.
The total number of shares in Elekta as of June 8, 2010 was 92,795,244 shares
and Elekta currently does not hold any shares in the Company.
Purchases will be made on NASDAQ OMX Stockholm and at a price within the spread
at the time of the purchase. Purchases can be made during the time until next
Annual General Meeting.
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb.
This information was brought to you by Cision http://www.cisionwire.com
Stina Thorman, Vice President Corporate Communications
Tel: +46 8 587 254 37
Copyright Business Wire 2010